CO2019003440A2 - Derivados de 5-[2-(pirldin-2-ilamino)-1,3-tiazol-5-il]-2,3-dihidro-1h-isoindol-1-ona y su uso como inhibidores dobles de fosfatidilinositol··3-cinasa delta y gamma - Google Patents

Derivados de 5-[2-(pirldin-2-ilamino)-1,3-tiazol-5-il]-2,3-dihidro-1h-isoindol-1-ona y su uso como inhibidores dobles de fosfatidilinositol··3-cinasa delta y gamma

Info

Publication number
CO2019003440A2
CO2019003440A2 CONC2019/0003440A CO2019003440A CO2019003440A2 CO 2019003440 A2 CO2019003440 A2 CO 2019003440A2 CO 2019003440 A CO2019003440 A CO 2019003440A CO 2019003440 A2 CO2019003440 A2 CO 2019003440A2
Authority
CO
Colombia
Prior art keywords
phosphatidylinositol
pyrldin
isoindole
ylamino
thiazol
Prior art date
Application number
CONC2019/0003440A
Other languages
English (en)
Spanish (es)
Inventor
Matthew Perry
Konstantinos Karabelas
Mickael Mogemark
Peter Bold
Christian Tyrchan
Antonios Nikitidis
Jens Petersen
Ulf Börjesson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO2019003440A2 publication Critical patent/CO2019003440A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2019/0003440A 2016-09-22 2019-04-08 Derivados de 5-[2-(pirldin-2-ilamino)-1,3-tiazol-5-il]-2,3-dihidro-1h-isoindol-1-ona y su uso como inhibidores dobles de fosfatidilinositol··3-cinasa delta y gamma CO2019003440A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662398006P 2016-09-22 2016-09-22
PCT/EP2017/073916 WO2018055040A1 (en) 2016-09-22 2017-09-21 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1 h-isoindol-1 -one derivatives and their use as dual inhibitors of phosphatidylinositol 3-kinase delta & gamma

Publications (1)

Publication Number Publication Date
CO2019003440A2 true CO2019003440A2 (es) 2019-04-12

Family

ID=59966739

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0003440A CO2019003440A2 (es) 2016-09-22 2019-04-08 Derivados de 5-[2-(pirldin-2-ilamino)-1,3-tiazol-5-il]-2,3-dihidro-1h-isoindol-1-ona y su uso como inhibidores dobles de fosfatidilinositol··3-cinasa delta y gamma

Country Status (36)

Country Link
US (2) US10961236B2 (enExample)
EP (1) EP3515910B1 (enExample)
JP (1) JP6765516B2 (enExample)
KR (1) KR102226098B1 (enExample)
CN (1) CN109715623A (enExample)
AR (1) AR109706A1 (enExample)
AU (1) AU2017331940B2 (enExample)
BR (1) BR112019004719A2 (enExample)
CA (1) CA3036304A1 (enExample)
CL (1) CL2019000707A1 (enExample)
CO (1) CO2019003440A2 (enExample)
CR (1) CR20190200A (enExample)
CY (1) CY1123346T1 (enExample)
DK (1) DK3515910T3 (enExample)
DO (1) DOP2019000073A (enExample)
EA (1) EA036176B1 (enExample)
EC (1) ECSP19027780A (enExample)
ES (1) ES2818583T3 (enExample)
HR (1) HRP20201175T1 (enExample)
HU (1) HUE051634T2 (enExample)
IL (1) IL265298B (enExample)
JO (1) JOP20190052A1 (enExample)
LT (1) LT3515910T (enExample)
MA (1) MA46268B1 (enExample)
MX (2) MX381898B (enExample)
PE (1) PE20190909A1 (enExample)
PH (1) PH12019500615A1 (enExample)
PL (1) PL3515910T3 (enExample)
PT (1) PT3515910T (enExample)
RS (1) RS60764B1 (enExample)
SI (1) SI3515910T1 (enExample)
SM (1) SMT202000481T1 (enExample)
SV (1) SV2019005857A (enExample)
TW (1) TW201813967A (enExample)
UA (1) UA123558C2 (enExample)
WO (1) WO2018055040A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
US11078204B2 (en) 2018-11-13 2021-08-03 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
CA3134173A1 (en) * 2019-04-10 2020-10-15 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphatidylinositol 3-kinase inhibitors
EP3980010A4 (en) 2019-06-04 2023-06-07 Arcus Biosciences, Inc. 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS
CN114258393B (zh) * 2020-07-21 2024-11-22 中国医药研究开发中心有限公司 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途
WO2022023456A1 (en) 2020-07-29 2022-02-03 Astrazeneca Ab Pharmaceutical compositions comprising nano embedded microparticles and methods of use
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0303538A2 (hu) * 2000-12-21 2005-02-28 Bristol-Myers Squibb Co. Tirozin kinázok Tec családjának tiazolil-vegyület inhibitorai és ezeket tartalmazó gyógyszerkészítmények
GB0305152D0 (en) * 2003-03-06 2003-04-09 Novartis Ag Organic compounds
GB0320197D0 (en) * 2003-08-28 2003-10-01 Novartis Ag Organic compounds
US20090233896A1 (en) * 2005-06-09 2009-09-17 Arrington Kenneth L Inhibitors of checkpoint kinases
TW200911798A (en) * 2007-08-02 2009-03-16 Amgen Inc PI3 kinase modulators and methods of use
UY33337A (es) * 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CA2850763A1 (en) 2011-10-04 2013-04-11 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
AR094797A1 (es) 2013-02-15 2015-08-26 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
US11352359B2 (en) 2013-07-02 2022-06-07 Rhizen Pharmaceuticals Ag PI3K protein kinase inhibitors
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
SG11201610745XA (en) 2014-06-27 2017-01-27 Rhizen Pharmaceuticals Sa Substituted chromene derivatives as selective dual inhibitors of pi3 delta and gamma protein kinases

Also Published As

Publication number Publication date
RS60764B1 (sr) 2020-10-30
EP3515910A1 (en) 2019-07-31
PT3515910T (pt) 2020-09-16
US10961236B2 (en) 2021-03-30
IL265298A (en) 2019-05-30
HRP20201175T1 (hr) 2020-11-13
PL3515910T3 (pl) 2021-02-22
MX2019003194A (es) 2019-06-17
MX2021004748A (es) 2021-06-08
ES2818583T3 (es) 2021-04-13
JP6765516B2 (ja) 2020-10-07
CA3036304A1 (en) 2018-03-29
DOP2019000073A (es) 2019-04-15
US20200308164A1 (en) 2020-10-01
CY1123346T1 (el) 2022-03-24
SV2019005857A (es) 2019-05-06
EA036176B1 (ru) 2020-10-09
UA123558C2 (uk) 2021-04-21
MA46268A (fr) 2019-07-31
CL2019000707A1 (es) 2019-05-31
CN109715623A (zh) 2019-05-03
MA46268B1 (fr) 2020-08-31
JP2019529445A (ja) 2019-10-17
IL265298B (en) 2020-09-30
AU2017331940A1 (en) 2019-05-02
PH12019500615A1 (en) 2019-06-03
KR20190049867A (ko) 2019-05-09
AU2017331940B2 (en) 2020-03-12
AR109706A1 (es) 2019-01-16
EP3515910B1 (en) 2020-07-15
HUE051634T2 (hu) 2021-03-01
BR112019004719A2 (pt) 2019-05-28
TW201813967A (zh) 2018-04-16
SMT202000481T1 (it) 2020-11-10
PE20190909A1 (es) 2019-06-26
US20210246130A1 (en) 2021-08-12
WO2018055040A1 (en) 2018-03-29
SI3515910T1 (sl) 2020-09-30
LT3515910T (lt) 2020-10-12
MX381898B (es) 2025-03-13
EA201990664A1 (ru) 2019-08-30
CR20190200A (es) 2019-06-07
JOP20190052A1 (ar) 2019-03-21
DK3515910T3 (da) 2020-08-31
KR102226098B1 (ko) 2021-03-09
ECSP19027780A (es) 2019-04-30

Similar Documents

Publication Publication Date Title
CO2019003440A2 (es) Derivados de 5-[2-(pirldin-2-ilamino)-1,3-tiazol-5-il]-2,3-dihidro-1h-isoindol-1-ona y su uso como inhibidores dobles de fosfatidilinositol··3-cinasa delta y gamma
DOP2016000175A (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
MX2018010894A (es) Nuevos inhibidores de fosfatidilinositol 3-quinasa gamma.
CO2019008986A2 (es) Derivados de tirosinamida como inhibidores de rho-quinasa
BR112016022598A8 (pt) composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso
BR112014026643A2 (pt) derivados de imidazotiadiazol e imidazopirazina como inibidores de receptor 4 ativado por protease (par4) para o tratamento de agregação de plaqueta
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
EA201650029A1 (ru) Пиразолопиридины и пиразолопиримидины
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
AR096543A1 (es) INHIBIDORES DE QUINASA PI3 d Y g SELECTIVOS DUALES
BR112017010439A2 (pt) composto, composição farmacêutica, combinação farmacêutica, kit, métodos para controle de uma doença fúngica em uma planta e para prevenção ou tratamento de doença fúngica em um indivíduo, e, uso de um composto
DOP2014000271A (es) Nueva forma de dosificacion y formulacion de abediterol
CU20140037A7 (es) Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
UY33191A (es) Derivados de pirazina
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
BR112015013414A2 (pt) derivados de naftiridona e seu uso no tratamento, melhora ou prevenção de uma doença viral
AR104504A1 (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
AR105921A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos